Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia—The Future Is Here

Melody Hermel; Madison Lieberman; Leandro Slipczuk; Jamal S. Rana; Salim S. Virani

doi:10.3390/pharmaceutics15020459

Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia—The Future Is Here

Melody Hermel, Madison Lieberman, Leandro Slipczuk, Jamal S. Rana, Salim S. Virani

Medicine

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

Hyperlipidemia is a significant risk factor for atherosclerotic cardiovascular disease. Undertreatment of elevated lipids persists despite existing therapies. Here, we provide an update on monoclonal antibodies, gene silencing therapies, and gene editing techniques for the management of hyperlipidemia. The current era of cutting-edge pharmaceuticals targeting low density lipoprotein cholesterol, PCSK9, lipoprotein (a), angiopoietin-like 3, and apolipoprotein C3 are reviewed. We outline what is known, studies in progress, and futuristic goals. This review of available and upcoming biotechnological lipid therapies is presented for clinicians managing patients with familial hyperlipidemia, statin intolerance, hypertriglyceridemia, or elevated lipoprotein (a) levels.

Original language	English (US)
Article number	459
Journal	Pharmaceutics
Volume	15
Issue number	2
DOIs	https://doi.org/10.3390/pharmaceutics15020459
State	Published - Feb 2023

Keywords

atherosclerotic cardiovascular disease
cardiovascular prevention
hyperlipidemia
hypertriglyceridemia
lipoprotein (a)

ASJC Scopus subject areas

Pharmaceutical Science

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/pharmaceutics15020459

Cite this

@article{ce2110211a574b55b75fb17474e0ae06,

title = "Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia—The Future Is Here",

abstract = "Hyperlipidemia is a significant risk factor for atherosclerotic cardiovascular disease. Undertreatment of elevated lipids persists despite existing therapies. Here, we provide an update on monoclonal antibodies, gene silencing therapies, and gene editing techniques for the management of hyperlipidemia. The current era of cutting-edge pharmaceuticals targeting low density lipoprotein cholesterol, PCSK9, lipoprotein (a), angiopoietin-like 3, and apolipoprotein C3 are reviewed. We outline what is known, studies in progress, and futuristic goals. This review of available and upcoming biotechnological lipid therapies is presented for clinicians managing patients with familial hyperlipidemia, statin intolerance, hypertriglyceridemia, or elevated lipoprotein (a) levels.",

keywords = "atherosclerotic cardiovascular disease, cardiovascular prevention, hyperlipidemia, hypertriglyceridemia, lipoprotein (a)",

author = "Melody Hermel and Madison Lieberman and Leandro Slipczuk and Rana, {Jamal S.} and Virani, {Salim S.}",

note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = feb,

doi = "10.3390/pharmaceutics15020459",

language = "English (US)",

volume = "15",

journal = "Pharmaceutics",

issn = "1999-4923",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "2",

}

TY - JOUR

T1 - Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia—The Future Is Here

AU - Hermel, Melody

AU - Lieberman, Madison

AU - Slipczuk, Leandro

AU - Rana, Jamal S.

AU - Virani, Salim S.

PY - 2023/2

Y1 - 2023/2

N2 - Hyperlipidemia is a significant risk factor for atherosclerotic cardiovascular disease. Undertreatment of elevated lipids persists despite existing therapies. Here, we provide an update on monoclonal antibodies, gene silencing therapies, and gene editing techniques for the management of hyperlipidemia. The current era of cutting-edge pharmaceuticals targeting low density lipoprotein cholesterol, PCSK9, lipoprotein (a), angiopoietin-like 3, and apolipoprotein C3 are reviewed. We outline what is known, studies in progress, and futuristic goals. This review of available and upcoming biotechnological lipid therapies is presented for clinicians managing patients with familial hyperlipidemia, statin intolerance, hypertriglyceridemia, or elevated lipoprotein (a) levels.

AB - Hyperlipidemia is a significant risk factor for atherosclerotic cardiovascular disease. Undertreatment of elevated lipids persists despite existing therapies. Here, we provide an update on monoclonal antibodies, gene silencing therapies, and gene editing techniques for the management of hyperlipidemia. The current era of cutting-edge pharmaceuticals targeting low density lipoprotein cholesterol, PCSK9, lipoprotein (a), angiopoietin-like 3, and apolipoprotein C3 are reviewed. We outline what is known, studies in progress, and futuristic goals. This review of available and upcoming biotechnological lipid therapies is presented for clinicians managing patients with familial hyperlipidemia, statin intolerance, hypertriglyceridemia, or elevated lipoprotein (a) levels.

KW - atherosclerotic cardiovascular disease

KW - cardiovascular prevention

KW - hyperlipidemia

KW - hypertriglyceridemia

KW - lipoprotein (a)

UR - http://www.scopus.com/inward/record.url?scp=85149108488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85149108488&partnerID=8YFLogxK

U2 - 10.3390/pharmaceutics15020459

DO - 10.3390/pharmaceutics15020459

M3 - Review article

AN - SCOPUS:85149108488

SN - 1999-4923

VL - 15

JO - Pharmaceutics

JF - Pharmaceutics

IS - 2

M1 - 459

ER -

Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia—The Future Is Here

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this